Prophylaxis Against Influenza
Conditions
Brief summary
The primary objective is to demonstrate the immunological non-inferiority between GC3102C and GC FLU inj. influenza vaccines by assessing geometric mean titers(GMTs) in healthy adults
Interventions
BIOLOGICALGC3102C
a single dose (0.5 mL) intramuscularly on the deltoid muscle
BIOLOGICALGC FLU inj.
a single dose (0.5 mL) intramuscularly on the deltoid muscle
Sponsors
Green Cross Corporation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy adults, 18 to \<60 years old * Subjets willing to provide written informed consent and able to comply with the requirements for the study
Exclusion criteria
* Subjects with a history of hypersensitivity, especially anaphylactic reactions to egg, egg proteins, chicken or components of vaccine such as gentamicin, gelatin, and arginine * Subjects with a history of Guillain-Barré syndrome * Subjects with severe chronic diseases (e.g., cardiovascular diseases without controllable hypertension, hemoglobinopathy, respiratory, metabolic, and renal disorders) who are considered by the investigator to be ineligible for the study * Subjects previously treated with anti-coagulant therapy or hemophiliac patients who may be at risk of severe hemorrhage after an intramuscular injection * Subjects who have had an acute febrile (at least 38.0°C) episode at some time during the 72 hours before enrollment * Subjects who have received a vaccination within 7 days before enrollment or who are scheduled for another vaccination (excluding the study vaccine) during the study * Immunocompromised subjects with immunodeficiency diseases or those who are receiving immunosuppressive or immunomodulatory therapy, e.g., azathioprine, cyclosporin, interferon, granulocyte-colony stimulating factor, tacrolimus, everolimus, sirolimus * Subjects who have received high-dose corticosteroids in the 3 months before vaccination or who will be administered a cumulative dose of 700 mg of corticosteroids during the study. Inhaled, intranasal, and local application of corticosteroids is permitted, regardless of dosage, and corticosteroids such as prednisolone at a maximum dose of 15 mg/day are allowed * Subjects who have been administered immunoglobulins or blood-derived products 3 months before enrollment or who are scheduled for the administration during the study * Subjects who have received an influenza vaccine within 6 months of enrollment * A female subject who is pregnant or who is breast-feeding. Subjects of childbearing potential without an appropriate contraceptive measure within 30 days before enrollment and who do not agree to use a clinically acceptable method of birth control during the study (e.g., oral contraceptives, condom, diaphragm or intrauterine device, or vasectomy of male partner) * Subjects who have participated in any other clinical trials within 30 days of the administration of the study vaccine * Individuals with other clinically significant medical or psychological condition who are considered by the investigator to be ineligible for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| GMT, using the Hemagglutination inhibition(HI) antibody titer | Day 21 |
Secondary
| Measure | Time frame |
|---|---|
| Rate of subjects achieving seroconversion | Day 0 , Day 21 |
| Rate of subjects achieving seroprotection | Day 21 |
| Number of Participants Reporting a Solicited Adverse Events After Vaccination | Day 6 |
| Number of Participants Reporting a Unsolicited Adverse Events After Vaccination | Day 21 |
Outcome results
None listed